



***ANABION***

# Next-in-Science of Human

## Overview

ANABION is an international biotech company based in Doha, Qatar.

Driven by the mission of helping people live longer and healthier lives, we strive for providing effective, safe and affordable solutions in life sciences.


**ANABION**

## Our Strengths

- Strong portfolio to help patients with life threatening diseases
- Fast access to numerous international markets
- Rapidly developing R&D infrastructure and commercial-scale manufacturing
- Comprehensive medical and marketing expertise to support our partners
- Tailored business models for each partner & market needs: distribution, co-promotion, partnering in manufacturing, etc.

# ANABION Global Network

We have extensive network in the Middle East, Africa, Southeast Asia and Latin America



# Global Pharmaceutical Registrations Overview

## Approved

86 marketing authorizations  
25 countries  
16 pharmaceutical products

## Submitted

59 dossiers submitted  
19 countries  
14 pharmaceutical products.

## Planned

114 dossiers planned for submission  
19 countries  
20 pharmaceutical products



# Advanced Biotech & Logistic Headquarter

Ras Bufontas Free Zone Doha, Qatar



\* Manufacturing site under construction

## Portfolio and Future Pipeline

*ANABION* can provide innovative original treatment options, biosimilars to most significant drugs and gene therapies used to help patients with diseases in the following therapeutic areas:

- Oncology
- Autoimmune diseases
- Rare diseases (such as SMA, hemophilia etc.)

***ANABION***



# Portfolio

## ONCOLOGY

<b>Prolgolimab</b>	Original Mab	Advanced Melanoma, NSCLC
Prolgolimab + Nurulimab	Original Mab	Unresectable or metastatic Melanoma, Phase III trials in Neoadjuvant melanoma are ongoing
Pembrolizumab	Biosimilar	NSCLC, Melanoma, Hodgkin Lymphoma, Cervical cancer etc.
Bevacizumab	Biosimilar	NSCLC, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
Trastuzumab	Biosimilar	HER2+ BC, HER2+ Gastric Cancer
Rituximab	Biosimilar	non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis
Lenalidomide	Generic	Multiple Myeloma; Myelodysplastic Syndrome; Mantle cell Lymphoma
Fulvestrant	Generic	HR-positive, HER2-negative advanced or metastatic Breast Cancer
Abiraterone	Generic	Metastatic castration-resistant Prostate Cancer

# Portfolio

## AUTOIMMUNE DISEASES

Netakimab	Original Mab	Plaque Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis
Levilimab	Original Mab	Rheumatoid Arthritis, COVID-19
Adalimumab	Biosimilar	Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's disease, Ulcerative Colitis, Psoriasis, Psoriatic Arthritis, Uveitis
Infliximab	Biosimilar	Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's disease, Ulcerative Colitis, Psoriasis, Psoriatic arthritis
Divozilimab	Original Mab	RRMS 2L, Relapsing SPMS
Sampegininterferon beta-1a	Original bio	RRMS 1L
Interferon beta-1b	Biosimilar	RRMS 1L, CIS, SPMS
Interferon beta-1a	Biosimilar	RRMS 1L, first clinical demyelinating event
Darbepoetin alfa	Biosimilar	Chronic Kidney Disease-Associated Anemia
Eculizumab	Biosimilar	Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis

## MULTIPLE SCLEROSIS

## OTHER

# ANABION



Company  
Anabion Investments  
Holding LLC



Address Office No. 1004  
& 1005, 10th Floor, Y  
Tower, Lusail – Qatar



Email  
[info@anabion.com](mailto:info@anabion.com)